Concr

Concr is a mission-driven techbio company that utilizes established methods from astrophysics to accurately predict patient outcomes and treatment response to novel and existing cancer therapies. Its unique approach enables iterative learning between disparate and fragmented data across all stages of a drug’s journey into the clinic, eliminating the need for 'big data' and yielding the most accurate multi-modal tumor models.

Concr's cloud native platform – FarrSight® – empowers researchers to computationally simulate clinical trials, make advanced predictions about therapeutic response and biomarkers, and perform standard bioinformatics analyses directly. Headquartered in London, the company has a wholly-owned subsidiary in Brisbane, Australia.

Since its establishment in 2018, Concr has garnered attention and investment from notable organizations. The company has received backing from a range of investors, including University of Cambridge Enterprise, R42 Group, Oncology Ventures, Debiopharm, Cambridge Angels, Deep Science Ventures, SyndicateRoom, and most recently, Innovate UK.

With a focus on the biopharma and biotechnology industries, Concr aims to revolutionize precision therapy for all, backed by its innovative approach and strong support from the investment community.